IMMUTEP LTD-SP ADR (IMMP) Stock News

USA - NASDAQ:IMMP - US45257L1089 - ADR

1.74 USD

+0.05 (+2.96%)

Last: 11/10/2025, 8:00:02 PM

1.7793 USD

+0.04 (+2.26%)

After Hours: 11/10/2025, 8:00:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

IMMP Latest News, Press Relases and Analysis

All

Press Releases

22 days ago - By: Immutep Limited

Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025

a month ago - By: Immutep Limited

Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer

a month ago - By: Immutep Limited

Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer

2 months ago - By: Immutep Limited

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

3 months ago - By: Immutep Limited

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer

4 months ago - By: Yahoo Finance

Immutep (IMMP) Announces Positive Initial Efficacy Data and Continued Favourable Safety Data

5 months ago - By: Immutep Limited

Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases

6 months ago - By: Immutep Limited

Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

6 months ago - By: Benzinga - Mentions: CVM BCLI LIPO BDSX ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

6 months ago - By: Benzinga - Mentions: MRK

Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo

6 months ago - By: Immutep Limited

Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer

7 months ago - By: Immutep Limited

Immutep Quarterly Activities Report Q3 FY25

7 months ago - By: Immutep Limited

Immutep to Participate in Upcoming Investor Conferences

8 months ago - By: Immutep Limited

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025

9 months ago - By: Immutep Limited

Immutep Quarterly Activities Report Q2 FY25

a year ago - By: Immutep Limited

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

a year ago - By: Immutep Limited

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

a year ago - By: Immutep Limited

Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

a year ago - By: Immutep Limited

Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

a year ago - By: Immutep Limited

Immutep Quarterly Activities Report Q1 FY25

a year ago - By: Immutep Limited

Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024

a year ago - By: Immutep Limited

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

a year ago - By: Immutep Limited

Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

a year ago - By: Immutep Limited

Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody

a year ago - By: Immutep Limited

Immutep to Participate in Upcoming Investor Conferences

a year ago - By: Immutep Limited

Immutep Quarterly Activities Report Q4 FY24

a year ago - By: Immutep Limited

Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer

a year ago - By: InvestorPlace - Mentions: CGBS TOYO SNTG ABVE ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

a year ago - By: Immutep Limited

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

a year ago - By: Immutep Limited

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results